TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32605885

Group type: EXPERIMENTAL
Intervention: Innovative whole-wheat synbiotic pasta
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control whole-wheat pasta
Number of subjects: 41
Study: 35709548

Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (40 international units)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study: 32939054

Group type: EXPERIMENTAL
Intervention: Nimotuzumab plus cisplatin radiation (NCRT)
Number of subjects: 404

Group type: COMPARATOR
Intervention: Cisplatin radiation (CRT)
Number of subjects: 404
Study: 33834490

Group type: EXPERIMENTAL
Intervention: Experimental group (clinical reasoning approach)
Number of subjects: 123176

Group type: COMPARATOR
Intervention: Usual care control group (FRAT)
Number of subjects: 123176
Study: 32146127

Group type: EXPERIMENTAL
Intervention: Molecular lymph node analysis using FXYD3
Number of subjects: 76
Study: 35606829

Group type: EXPERIMENTAL
Intervention: Empiric antibiotics (ampicillin and gentamicin)
Number of subjects: 802

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 802
Study: 33038017

Group type: EXPERIMENTAL
Intervention: Cosmetic treatment product
Number of subjects: 58

Group type: COMPARATOR
Intervention: Untreated control
Number of subjects: 58
Study: 35428344

Group type: EXPERIMENTAL
Intervention: NET alone
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: NET plus genealogical assessment
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 22
Study: 33749826

Group type: EXPERIMENTAL
Intervention: ubrogepant 50 mg
Number of subjects: 1799

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 1799
Study: 32534361

Group type: EXPERIMENTAL
Intervention: Mindfulness-based cognitive therapy (MBCT)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Psychoeducation (active control)
Number of subjects: 125
Study: 36370634

Group type: EXPERIMENTAL
Intervention: Inebilizumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 34806679

Group type: EXPERIMENTAL
Intervention: Renal Denervation (RDN)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham Control
Number of subjects: 0
Study: 35994847

Group type: EXPERIMENTAL
Intervention: Diterpene ginkgolides meglumine injection (DGMI)
Number of subjects: 399

Group type: COMPARATOR
Intervention: Ginaton
Number of subjects: 399
Study: 33974964

Group type: EXPERIMENTAL
Intervention: tDCS (n = 20)
Number of subjects: 60

Group type: COMPARATOR
Intervention: SHAM (n = 20)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control (n = 20)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 60
Study: 32571269

Group type: EXPERIMENTAL
Intervention: Resending the complete questionnaire to non-responders
Number of subjects: 1824

Group type: EXPERIMENTAL
Intervention: Telephone call to participants
Number of subjects: 1824
Study: 35217440

Group type: EXPERIMENTAL
Intervention: Tanezumab 2.5 mg, subcutaneous every 8 weeks for 56 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tanezumab 5 mg, subcutaneous every 8 weeks for 56 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oral NSAIDs, twice-daily for 56 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tanezumab 2.5 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tanezumab 5 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oral NSAIDs
Number of subjects: 0
Study: 32304415

Group type: EXPERIMENTAL
Intervention: 1‐deamino‐8‐D‐arginine vasopressin (0.4 µg/kg) + platelet transfusion (2 U)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: 1‐deamino‐8‐D‐arginine vasopressin + platelet transfusion
Number of subjects: 140
Study: 35087624

Group type: EXPERIMENTAL
Intervention: Carvedilol (CVD)
Number of subjects: 192

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 192
Study: 32453198

Group type: EXPERIMENTAL
Intervention: Metronidazole as part of multimodal therapy
Number of subjects: 55
Study: 35326010

Group type: EXPERIMENTAL
Intervention: 28‐kHz frequency
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: 42‐kHz frequency
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: 53‐kHz frequency
Number of subjects: 207
Study: 32271702

Group type: EXPERIMENTAL
Intervention: California's 2010 Healthy Beverages in Child Care Act adherence in 2016
Number of subjects: 680

Group type: EXPERIMENTAL
Intervention: Milk provision adherence
Number of subjects: 680

Group type: EXPERIMENTAL
Intervention: 100% juice provision adherence
Number of subjects: 680

Group type: EXPERIMENTAL
Intervention: Sugar-sweetened beverages provision adherence
Number of subjects: 680

Group type: COMPARATOR
Intervention: Adherence comparison between centers and homes
Number of subjects: 680

Group type: COMPARATOR
Intervention: Adherence comparison between CACFP and non-CACFP sites
Number of subjects: 680
Study: 34315481

Group type: EXPERIMENTAL
Intervention: GLAs with demonstrated cardiovascular benefit (e.g., glucagon‐like peptide‐1 receptor agonists and sodium‐glucose co‐transporter‐2 inhibitors)
Number of subjects: 9823

Group type: EXPERIMENTAL
Intervention: Overall CAPTURE sample
Number of subjects: 9823
Study: 36219998

Group type: EXPERIMENTAL
Intervention: Foot massage (8 sessions over 4 weeks)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 84
Study: 33429735

Group type: EXPERIMENTAL
Intervention: IVIg (Octagam 10%) 2 g/kg every 4 weeks until week 16
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: IVIg (Octagam 10%) 2 g/kg every 4 weeks for 24 weeks (open-label Extension Period)
Number of subjects: 0
Study: 32428937

Group type: EXPERIMENTAL
Intervention: Active serum and mask
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 35748112

Group type: EXPERIMENTAL
Intervention: Featback, an online unguided self‐help program
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chat or e‐mail support from a recovered expert patient
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Featback with expert‐patient support
Number of subjects: 0

Group type: COMPARATOR
Intervention: Care‐as‐usual
Number of subjects: 0
Study: 32722939

Group type: EXPERIMENTAL
Intervention: O3FAs/PPs group: Oral omega-3 fatty acids (O3FAs) two capsules twice daily (total daily dose of 1040 mg/day) for 6 months with punctal plugs.
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: PPs group: Punctal plugs with oral placebo.
Number of subjects: 90

Group type: COMPARATOR
Intervention: Isotretinoin group: No intervention.
Number of subjects: 90
Study: 34299917

Group type: EXPERIMENTAL
Intervention: Childcare PLAY policy implemented for eight weeks
Number of subjects: 148

Group type: COMPARATOR
Intervention: Control group continued typical daily routines
Number of subjects: 148
Study: 33246931

Group type: EXPERIMENTAL
Intervention: Nivolumab plus ipilimumab (NIVO+IPI)
Number of subjects: 1096

Group type: COMPARATOR
Intervention: Sunitinib (SUN)
Number of subjects: 1096
Study: 35218145

Group type: EXPERIMENTAL
Intervention: Family-based behavioural social facilitation treatment (FBSFT)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 114
Study: 36108881

Group type: EXPERIMENTAL
Intervention: Single-row repair with horizontal LHBT augmentation
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Single-row repair with v-shaped LHBT augmentation
Number of subjects: 18

Group type: COMPARATOR
Intervention: Traditional single-row repair
Number of subjects: 18
Study: 32589321

Group type: EXPERIMENTAL
Intervention: Peyronie patients with low testosterone levels
Number of subjects: 284

Group type: COMPARATOR
Intervention: Healthy volunteers
Number of subjects: 284

Group type: EXPERIMENTAL
Intervention: Peyronie patients
Number of subjects: 284
Study: 35466521

Group type: EXPERIMENTAL
Intervention: b.i.d. amoxicillin for 7 days
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: b.i.d. amoxicillin for 10 days
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: t.i.d. amoxicillin for 7 days
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: t.i.d. amoxicillin for 10 days
Number of subjects: 119
Study: 34412189

Group type: EXPERIMENTAL
Intervention: 5A teaching group
Number of subjects: 70
Study: 32469881

Group type: EXPERIMENTAL
Intervention: Functional cast position
Number of subjects: 105

Group type: COMPARATOR
Intervention: Volar-flexion and ulnar deviation cast
Number of subjects: 105
Study: 35081747

Group type: EXPERIMENTAL
Intervention: Atezolizumab + Bevacizumab prior to or in combination with TACE
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 32900913

Group type: COMPARATOR
Intervention: Ventilator settings (including ventilatory modes, triggering sensitivity, inspiratory pressurization, and inspiratory cycling-off)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Differences in pleural pressure levels between the nondependent (ND) and dependent (D) regions
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lung mechanics between the ND and D regions
Number of subjects: 0

Group type: COMPARATOR
Intervention: Gas flow from the D region to the ND region
Number of subjects: 0
Study: 35832028

Group type: EXPERIMENTAL
Intervention: Date seed powder (DSP, n=18)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Wheat bran powder (placebo, n=18)
Number of subjects: 36
Study: 33798298

Group type: EXPERIMENTAL
Intervention: Jin's three-needle therapy and motor relearning regimen
Number of subjects: 60

Group type: COMPARATOR
Intervention: Routine rehabilitation regimen (Control)
Number of subjects: 60
Study: 34763959

Group type: EXPERIMENTAL
Intervention: Affordable Care Act (ACA) removal of cost sharing for colorectal cancer screening
Number of subjects: 2113283

Group type: COMPARATOR
Intervention: Pre-ACA zero cost sharing for colorectal cancer screening
Number of subjects: 2113283
Study: 33188155

Group type: EXPERIMENTAL
Intervention: Endovascular thrombectomy (EVT)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: HERMES, DAWN, DEFUSE 3 trials (pivotal EVT trials)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Medical management (MM)
Number of subjects: 105
Study: 32735782

Group type: EXPERIMENTAL
Intervention: Cannabidiol 400 mg
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Cannabidiol 800 mg
Number of subjects: 82

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study: 32914666

Group type: EXPERIMENTAL
Intervention: Maximal Inspiratory Pressure (MIP)
Number of subjects: 61
Study: 33800775

Group type: EXPERIMENTAL
Intervention: Virtual Reality therapy and Mirror Therapy (MT)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Standard physiotherapy
Number of subjects: 59
Study: 32229194

Group type: EXPERIMENTAL
Intervention: Tranexamic acid 15 mg/kg
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 60
Study: 35803896

Group type: EXPERIMENTAL
Intervention: Interpersonal psychotherapy (IPT)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Antidepressant medication (ADM)
Number of subjects: 80
Study: 34365776

Group type: EXPERIMENTAL
Intervention: Metformin or sulfonylurea/metformin combination (Group 1)
Number of subjects: 264

Group type: EXPERIMENTAL
Intervention: Thiazolidinedione combination (Group 2)
Number of subjects: 264

Group type: EXPERIMENTAL
Intervention: Dipeptidyl peptidase‐4 inhibitor (gemigliptin) combination (Group 3)
Number of subjects: 264

Group type: EXPERIMENTAL
Intervention: Sodium‐glucose cotransporter 2 inhibitor (empagliflozin) combination (Group 4)
Number of subjects: 264

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 264
Study: 35484019

Group type: EXPERIMENTAL
Intervention: Behavioral Activation (BA) intervention
Number of subjects: 34

Group type: COMPARATOR
Intervention: Treatment as usual (control)
Number of subjects: 34
Study: 34112708

Group type: COMPARATOR
Intervention: fotemustine
Number of subjects: 80

Group type: COMPARATOR
Intervention: ipilimumab plus fotemustine
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: ipilimumab plus nivolumab
Number of subjects: 80
Study: 35988951

Group type: EXPERIMENTAL
Intervention: COVID-19-induced stress
Number of subjects: 1188

Group type: EXPERIMENTAL
Intervention: COVID-19-induced loneliness
Number of subjects: 1188

Group type: EXPERIMENTAL
Intervention: No limitation of physical interactions due to COVID-19
Number of subjects: 1188

Group type: EXPERIMENTAL
Intervention: Increased use of a food bank
Number of subjects: 1188

Group type: EXPERIMENTAL
Intervention: Negative change in financial situation
Number of subjects: 1188
Study: 32737054

Group type: EXPERIMENTAL
Intervention: dDAVP oral lyophilisate administered sublingually as a single dose after a water load.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: dDAVP oral lyophilisate
Number of subjects: 0
Study: 33947446

Group type: EXPERIMENTAL
Intervention: COVID-19 convalescent plasma (CCP) approximately 500 mL
Number of subjects: 1200

Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 1200
Study: 35762831

Group type: EXPERIMENTAL
Intervention: Peer data benchmarking report intervention
Number of subjects: 489

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 489
Study: 33535830

Group type: EXPERIMENTAL
Intervention: Two-handed jaw thrust (n = 46)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Conventional intubation with sham jaw thrust (n = 46)
Number of subjects: 92
Study: 35315323

Group type: EXPERIMENTAL
Intervention: Quadrivalent influenza vaccine (QIV)
Number of subjects: 2000

Group type: COMPARATOR
Intervention: Control vaccine
Number of subjects: 2000
Study: 34889041

Group type: EXPERIMENTAL
Intervention: Deep mode CO2 fractional laser (n=15)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Mid mode CO2 fractional laser (n=15)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Fusion mode CO2 fractional laser (n=30)
Number of subjects: 30
Study: 33369704

Group type: EXPERIMENTAL
Intervention: Rucaparib 500 mg twice daily
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Bevacizumab 15 mg/kg every 21 days
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Rucaparib 600 mg twice daily
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Rucaparib (various doses) with Bevacizumab
Number of subjects: 9
Study: 32715754

Group type: EXPERIMENTAL
Intervention: Fidaxomicin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vancomycin
Number of subjects: 0
Study: 33896233

Group type: EXPERIMENTAL
Intervention: Home-based palliative care
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Recommendations for improving home-based palliative care access
Number of subjects: 25
Study: 35767039

Group type: EXPERIMENTAL
Intervention: Early weight-bearing mobilization accelerated rehabilitation (AR group)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Traditional rehabilitation (TR group)
Number of subjects: 68
Study: 33955610

Group type: EXPERIMENTAL
Intervention: Binge eating frequency assessed on a recall basis for 4 weeks before and during lockdown
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: General ED pathology and depressive symptoms
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Emotion regulation strategy (reappraisal) and sense of coherence
Number of subjects: 0
Study: 32236828

Group type: EXPERIMENTAL
Intervention: Trastuzumab/pertuzumab
Number of subjects: 1230

Group type: EXPERIMENTAL
Intervention: TDM1
Number of subjects: 1230
Study: 36203695

Group type: EXPERIMENTAL
Intervention: Thirsty for a Smile intervention (home delivery of bottled water and dietary counseling)
Number of subjects: 22
Study: 32438988

Group type: EXPERIMENTAL
Intervention: Bleeding events
Number of subjects: 684

Group type: EXPERIMENTAL
Intervention: Bleeding within the first 2 days of hospitalization
Number of subjects: 684

Group type: EXPERIMENTAL
Intervention: Bleeding
Number of subjects: 684

Group type: EXPERIMENTAL
Intervention: Active mechanical support (extracorporeal membrane oxygenation or Impella)
Number of subjects: 684
Study: 33714479

Group type: EXPERIMENTAL
Intervention: Neural mobilization (NM) in addition to standard rehabilitation
Number of subjects: 24

Group type: COMPARATOR
Intervention: Standard rehabilitation (CTRL)
Number of subjects: 24
Study: 35761328

Group type: EXPERIMENTAL
Intervention: Endometrial ablation plus LNG-IUS
Number of subjects: 0

Group type: COMPARATOR
Intervention: Endometrial ablation alone
Number of subjects: 0
Study: 34585591

Group type: EXPERIMENTAL
Intervention: Early invasive coronary angiography (within 12 hours)
Number of subjects: 2147

Group type: COMPARATOR
Intervention: Standard invasive coronary angiography (48-72 hours)
Number of subjects: 2147
Study: 32757652

Group type: EXPERIMENTAL
Intervention: Early planned mobilization in the first 2 days after surgery
Number of subjects: 92

Group type: COMPARATOR
Intervention: Routine nursing care only (Control)
Number of subjects: 92
Study: 36474201

Group type: EXPERIMENTAL
Intervention: Structured Skills Training Group (SSTG)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Psychoeducational Control Intervention
Number of subjects: 128
Study: 34634163

Group type: EXPERIMENTAL
Intervention: Topical finasteride
Number of subjects: 458

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 458

Group type: COMPARATOR
Intervention: Oral finasteride
Number of subjects: 458
Study: 33034559

Group type: EXPERIMENTAL
Intervention: Quality Improvement (QI) coaching intervention
Number of subjects: 89
Study: 35500019

Group type: EXPERIMENTAL
Intervention: Expressive writing about future teaching-related events (n = 67)
Number of subjects: 129

Group type: COMPARATOR
Intervention: Control group writing about a walk in a forest and a city park (n = 62)
Number of subjects: 129
Study: 33127365

Group type: EXPERIMENTAL
Intervention: Stepwise decrease in NCPAP pressure to 3 cm H2O (wean group)
Number of subjects: 226

Group type: COMPARATOR
Intervention: Immediate cessation of NCPAP at 5 cm H2O (control group)
Number of subjects: 226
Study: 34241947

Group type: EXPERIMENTAL
Intervention: CoCr‐DCS
Number of subjects: 401

Group type: COMPARATOR
Intervention: Propensity-matched cohort (SS‐DCS)
Number of subjects: 401

Group type: COMPARATOR
Intervention: Propensity-matched cohort (SS‐BMS)
Number of subjects: 401
Study: 33926704

Group type: EXPERIMENTAL
Intervention: Administration of antithrombin III (n = 64)
Number of subjects: 141

Group type: COMPARATOR
Intervention: Non-administration of antithrombin III (n = 77)
Number of subjects: 141
Study: 32105889

Group type: EXPERIMENTAL
Intervention: Single-stage ERCP plus laparoscopic cholecystectomy (group A, n=39)
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: ERCP plus laparoscopic cholecystectomy in the same hospitalization (group B, n=43)
Number of subjects: 119

Group type: COMPARATOR
Intervention: Delayed cholecystectomy after ERCP (group C, n=37)
Number of subjects: 119
Study: 35224875

Group type: EXPERIMENTAL
Intervention: Laparoscopic Glissonian pedicle approach hemihepatectomy (LGAH)
Number of subjects: 190
Study: 34932660

Group type: EXPERIMENTAL
Intervention: Mucoadhesive patches delivering lidocaine and prilocaine hydrochlorides (1:1, 30 mg/patch)
Number of subjects: 58
Study: 33579279

Group type: EXPERIMENTAL
Intervention: Dementia Care Mapping (DCM) training
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Dementia Care Mapping (DCM) implementation
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Sustaining DCM
Number of subjects: 27
Study: 32638027

Group type: EXPERIMENTAL
Intervention: High physical exertion
Number of subjects: 1246

Group type: EXPERIMENTAL
Intervention: Low social support
Number of subjects: 1246

Group type: EXPERIMENTAL
Intervention: Working with arms above shoulder level
Number of subjects: 1246

Group type: EXPERIMENTAL
Intervention: Total incident UEMSD
Number of subjects: 1246
Study: 33634665

Group type: EXPERIMENTAL
Intervention: Treatment-While-Incarcerated (TWI)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Outpatient Treatment (OP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Waitlist-Control (WC)
Number of subjects: 0
Study: 36161136

Group type: EXPERIMENTAL
Intervention: FCHV-delivered intervention for 12 months
Number of subjects: 690

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 690

Group type: EXPERIMENTAL
Intervention: FCHV-delivered intervention
Number of subjects: 690
Study: 32050695

Group type: EXPERIMENTAL
Intervention: Dynamic whole-body strength training including 3 x 10 squat jumps with WB-EMS (EG)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Jump training without EMS (TG)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group performing daily soccer routine (CG)
Number of subjects: 30
Study: 616726149

Group type: EXPERIMENTAL
Intervention: Mist fan
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Cooling towel
Number of subjects: 35

Group type: COMPARATOR
Intervention: Passive-cooling (no intervention) control
Number of subjects: 35
Study: 36107530

Group type: EXPERIMENTAL
Intervention: Bevel facing dorsal direction (Group D)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Bevel facing left (Group L)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 2
Study: 33261542

Group type: EXPERIMENTAL
Intervention: Fructose (75g in 200mL solution)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Glucose (75g in 200mL solution)
Number of subjects: 16
Study: 32316801

Group type: EXPERIMENTAL
Intervention: Leucovorin rescue at 24 hours after HDMTX infusion
Number of subjects: 98

Group type: COMPARATOR
Intervention: Leucovorin rescue at 18 hours after HDMTX infusion
Number of subjects: 98
Study: 32748165

Group type: EXPERIMENTAL
Intervention: Double continuous suture
Number of subjects: 100

Group type: COMPARATOR
Intervention: Interrupted suture
Number of subjects: 100
Study: 36204974

Group type: EXPERIMENTAL
Intervention: CPT (Cognitive Processing Therapy)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: CPT combined with cognitive rehabilitation (SMART‐CPT)
Number of subjects: 80
Study: 33508496

Group type: EXPERIMENTAL
Intervention: Virtual-reality exposure in multiple contexts
Number of subjects: 30

Group type: COMPARATOR
Intervention: Virtual-reality exposure in single context
Number of subjects: 30
Study: 32448935

Group type: EXPERIMENTAL
Intervention: No episiotomy (study group)
Number of subjects: 676

Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 676
Study: 36151277

Group type: EXPERIMENTAL
Intervention: Toothbrushing and flossing (TB + DF)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Toothbrushing alone
Number of subjects: 75
Study: 32882429

Group type: EXPERIMENTAL
Intervention: MG probing plus post‐procedural topical sulfacetamide/prednisolone ointment (Blephamide®)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: MG probing plus post‐procedural lubricating ointment (GenTeal)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Sham probing plus GenTeal ointment
Number of subjects: 42